Aro Biotherapeutics Reports Therapeutic Potential of Centyrin – IFIH1 siRNA Conjugate for the Treatment of Type 1 Diabetes: news

Aro Biotherapeutics Unveils Therapeutic Potential of Centyrin-IFIH1 siRNA Conjugate in Type 1 Diabetes

PHILADELPHIA Aro Biotherapeutics has announced preclinical findings demonstrating the therapeutic potential of its proprietary Centyrin-targeted small interfering RNA (siRNA) conjugate designed to silence IFIH1 (interferon induced with helicase C domain 1) for the treatment of Type 1 Diabetes (T1D). The data highlights a targeted RNA interference (RNAi) approach aimed at halting the autoimmune cascade and preserving pancreatic beta-cell function.

The Role of IFIH1 (MDA5) in Type 1 Diabetes Pathogenesis

IFIH1, which encodes melanoma differentiation-associated protein 5 (MDA5), is a genetically and mechanistically validated target in autoimmune disorders. As an intracellular sensor of viral double-stranded RNA, overactivation or gain-of-function variants of IFIH1 trigger sustained type I interferon signaling and chronic inflammation. In Type 1 Diabetes, this aberrant innate immune activation accelerates the immune-mediated destruction of insulin-producing pancreatic beta cells.

By utilizing RNA interference to downregulate IFIH1 expression, the therapeutic conjugate aims to interrupt this pathway upstream, dampening localized inflammatory signals without broadly compromising systemic immunity.

Centyrin-Oligonucleotide Platform: Overcoming Extra-Hepatic Delivery Challenges

A major hurdle in translating siRNA therapeutics to non-liver diseases has been targeted cellular uptake. Aro Biotherapeutics addresses this limitation using its Centyrin platform:

• Engineered Protein Scaffolds: Centyrins are small (approximately 10 kDa), highly stable, engineered protein scaffolds derived from human fibronectin type III (FN3) domains.

• Receptor-Mediated Internalization: Optimized Centyrins bind specific cell-surface receptors, facilitating receptor-mediated endocytosis and functional delivery of the attached siRNA payload into target cells.

• Durable Gene Knockdown: Once internalized, the conjugated siRNA escapes endosomal entrapment to load into the RNA-induced silencing complex (RISC), mediating sustained degradation of target IFIH1 mRNA.

Preclinical Findings and Disease-Modifying Potential

In preclinical models, the Centyrin-IFIH1 siRNA conjugate demonstrated robust pharmacodynamic activity, achieving significant target gene knockdown in relevant tissue compartments. The therapeutic intervention showed measurable disease-modifying efficacy, including reduced inflammatory signaling and protection against accelerated disease progression.

Unlike conventional exogenous insulin replacement therapies that manage glycemic symptoms post-onset, targeting IFIH1 with targeted siRNA represents an upstream disease-modifying strategy intended to intervene in the autoimmune mechanism driving Type 1 Diabetes pathogenesis.

Future Development and Clinical Implications

These preclinical findings support the continued evaluation and translational development of Centyrin-siRNA conjugates as potential therapeutics for Type 1 Diabetes and related autoimmune conditions. Aro Biotherapeutics continues to expand its pipeline of extra-hepatic genetic medicines, evaluating tissue distribution, dosing regimens, and safety profiles as it advances toward potential clinical trials.